GRABAR LAW OFFICE INVESTIGATES CLAIMS ON BEHALF OF SHAREHOLDERS OF LANTHEUS HOLDINGS, INC. (NASDAQ: LNTH)
Grabar Law Office is investigating claims on behalf of shareholders of Lantheus Holdings, Inc. (NASDAQ: LNTH). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company engaged in delivering science to enable clinicians to find, fight and follow diseases to deliver patient outcomes. The Company classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Radiopharmaceutical Oncology diagnostics and therapeutics help healthcare professionals (HCPs) find, fight and follow cancer, with a focus on prostate cancer. Precision Diagnostic products assist HCPs to find and follow diseases, with a focus on cardiology. Strategic Partnerships focus on enabling precision medicine through the use of biomarker solutions, digital solutions, and radiotherapeutic platforms. Its commercial products include PYLARIFY, DEFINITY, TechneLite, Neuraceq, and others. Its clinical candidates include LNTH-2404, NAV-4694, and PNT2002, among others. The Neuraceq (florbetaben F18 injection) is an F-18 PET imaging agent for Alzheimer’s disease.
As alleged in a recently filed federal securities fraud class action complaint, Lantheus Holdings, Inc. (NASDAQ: LNTH), through certain of its officers, defendants made false statements and/or concealed that: defendants created the false impression that they possessed reliable information pertaining to the Company's projected revenue outlook and anticipated growth while also minimizing risk from competition and pricing dynamics, seasonality, and macroeconomic fluctuations. In truth, Lantheus' optimistic reports of Pylarify's sales growth potential and pricing normalization fell short of reality; Lantheus, despite defendants claims, did not have an accurate understanding of the pricing and competitive dynamics of Pylarify's market.
WHAT YOU CAN DO NOW: If you purchased Lantheus Holdings, Inc. (NASDAQ: LNTH), shares prior to February 26, 2025, and still hold shares today, you are encouraged to contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Alternatively, if you purchased Lantheus shares between February 26, 2025, to August 5, 2025, you can participate in the class action.